Abstract
A cytotoxic T lymphocyte (CTL) clone generated in vitro from the peripheral blood of a healthy HLA-A2-positive individual against a synthetic p53 protein-derived wild-type peptide (L9V) was shown to kill squamous carcinoma cell lines derived from two head and neck carcinomas, which expressed mutant p53 genes, in a L9V/HLA-A2 specific and restricted fashion. Thus, the normal tolerance against endogenously processed p53 protein-derived self-epitopes can be broken by peptide-specific in vitro priming. p53 protein-derived wild-type peptides might thus represent tumor associated target molecules for immunotherapeutical approaches.
Original language | English |
---|---|
Journal | Proceedings of the National Academy of Sciences of the United States of America |
Volume | 93 |
Issue number | 25 |
Pages (from-to) | 14704-7 |
Number of pages | 4 |
ISSN | 0027-8424 |
Publication status | Published - 10 Dec 1996 |
Keywords
- Carcinoma, Squamous Cell
- Cytotoxicity, Immunologic
- HLA-A2 Antigen
- Head and Neck Neoplasms
- Humans
- Mutation
- T-Lymphocytes, Cytotoxic
- Tumor Cells, Cultured
- Tumor Suppressor Protein p53